ZyVersa Therapeutics, Inc. (ZVSA)

6.47 +0.08 (+1.25%) 收市：04:00PM EDT

ZyVersa Therapeutics, Inc.

2200 N. Commerce Parkway
Suite 208
Weston, FL 33326
United States
754 231 1688
https://www.zyversa.com

版塊: Healthcare
行業: Biotechnology
全職員工: 7

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Stephen C. Glover	Co-Founder, Chairman, CEO & President	775k	無	1960
Mr. Peter Wolfe	CFO & Secretary	477.5k	無	1968
Ms. Karen A. Cashmere	Chief Commercial Officer	410k	無	1952
Ms. Melda Uzbil O'connell	Senior Vice President of Corporate Development	無	無	無
Dr. Pablo A. Guzman FACC, M.D.	Chief Medical Officer, Senior VP of Medical Affairs & Chairman of Renal Scientific Advisory Board	無	無	1950

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.

公司管治

截至 無 止，ZyVersa Therapeutics, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。